Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment

Hepatocellular carcinoma in patients without advanced fibrosis after eradication of HCV with antiviral treatment

Bibliographic Details
Main Authors:	Yolanda Sánchez-Torrijos, Jara Eloísa Ternero-Vega, Carmen Cepeda-Franco
Format:	Article
Language:	English
Published:	Aran Ediciones
Series:	Revista Espanola de Enfermedades Digestivas
Online Access:	http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082017001000012&lng=en&tlng=en

Similar Items

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
by: Tatsuya Minami, et al.
Published: (2021-06-01)

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis.
by: Kazumichi Abe, et al.
Published: (2020-01-01)

Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control
by: Pierre Nahon, et al.
Published: (2021-01-01)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents
by: Marco Sanduzzi-Zamparelli, et al.
Published: (2019-05-01)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
by: Yuko Nagaoki, et al.
Published: (2017-01-01)

Management of patients with pre-therapeutic advanced liver fibrosis following HCV eradicationKey points
by: Pierre Nahon, et al.
Published: (2019-12-01)

Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy
by: M.G. Deneke, et al.
Published: (2014-01-01)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
by: Calogero Armando, et al.
Published: (2019-01-01)

Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
by: Mohamed Mohei El Badry, et al.
Published: (2020-11-01)

Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness
by: Elton Dajti, et al.
Published: (2021-06-01)

Chronic HCV Infection: Clinical Advances and Eradication Perspectives
Published: (2022)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
by: Armando Calogero, et al.
Published: (2019-01-01)

Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
by: Dash S, et al.
Published: (2020-04-01)

Whether antiviral therapy can reduce the incidence of hepatocellular carcinoma in patients with chronic HCV infection
by: ZENG Qinglei, et al.
Published: (2017-06-01)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
by: Hye Won Lee, et al.
Published: (2020-11-01)

Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection – A Real-World Cohort Study
by: Luo Y, et al.
Published: (2020-07-01)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals <sup>†</sup>
by: Silvia Molina-Carrión, et al.
Published: (2020-07-01)

Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration
by: Rosa Zampino, M.D. Ph.D., et al.
Published: (2015-01-01)

Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
by: Cátia Dias, et al.
Published: (2018-01-01)

Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction?
by: Shih-Jer Hsu, et al.
Published: (2020-01-01)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
by: Naoki Kawagishi, et al.
Published: (2018-01-01)

Risk of Hepatocellular Carcinoma after HCV Clearance by Direct-Acting Antivirals Treatment Predictive Factors and Role of Epigenetics
by: Luca Rinaldi, et al.
Published: (2020-05-01)

Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis
by: Angelo Sangiovanni, et al.
Published: (2021-01-01)

Serum Markers of Epithelial Mesenchymal Transition as Predictors of HCV-induced Liver Fibrosis, Cirrhosis and Hepatocellular Carcinoma
by: Mona M Zoheiry, et al.
Published: (2015-12-01)

Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C–Related Advanced Fibrosis and Cirrhosis
by: Kilany S, et al.
Published: (2021-08-01)

Efficacy of Transarterial Chemoembolisation with or without Antiviral Therapy for Patients with Hepatocellular Carcinoma after Radical Hepatectomy
by: Yin Zhu, et al.
Published: (2018-01-01)

Pathogenesis of hepatocellular carcinoma induced by HBV and HCV infection
by: WANG Yuejiao, et al.
Published: (2017-07-01)

HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation
by: Juliet A. Emamaullee, et al.
Published: (2019-01-01)

Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication
by: Qian Kang, et al.
Published: (2020-01-01)

Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis.
by: Valeria De Giorgi, et al.
Published: (2013-01-01)

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma
by: Buonaguro Luigi, et al.
Published: (2009-10-01)

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
by: Chung-Feng Huang, et al.
Published: (2019-03-01)

Whole Genome 5′-Methylcytosine Level Quantification in Cirrhotic HCV-Infected Egyptian Patients with and without Hepatocellular Carcinoma
by: Ahmed M. Awad, et al.
Published: (2020-01-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
by: Byung Soo Kwan, et al.
Published: (2021-03-01)

Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC)
by: Pin Zhao, et al.
Published: (2021-07-01)

Seroprevalence of HBV and HCV in primary hepatocellular carcinoma patients in Zimbabwe
by: Chavhunduka Evans, et al.
Published: (2009-10-01)

Hepatocellular carcinoma with a direct right atrial extension in an HCV patient previously treated with direct-acting antiviral therapy: a case report
by: Mahmoud Abdelnabi, et al.
Published: (2019-09-01)

Persistence of Hepatocellular Carcinoma Risk after Hepatitis C Virus Eradication
by: Sojung Han, et al.
Published: (2020-05-01)

Hepatocellular Carcinoma Risk, Outcomes, and Screening After Hepatitis C Eradication
by: Roberta D’Ambrosio, et al.
Published: (2021-09-01)

Sarcoidosis during HCV antiviral therapy
by: Emanuela De Santis, et al.
Published: (2014-08-01)